Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options

Authors: Mititelu, Alina; Onisai, Minodora-Cezarina; Rosca, Adrian; Vladareanu, Ana Maria

Affiliations: Carol Davila Univ Med & Pharm, Emergency Univ Hosp Bucharest, Dept Hematol, Bucharest 050098, Romania. Carol Davila Univ Med & Pharm, Dept Physiol, Bucharest 050471, Romania.

Publication: International journal of molecular sciences. 2024. 25

ABSTRACT: The management of immune thrombocytopenia (ITP) and the prediction of patient response to therapy still represent a significant and constant challenge in hematology. ITP is a heterogeneous disease with an unpredictable evolution. Although the pathogenesis of ITP is currently better known and its etiology has been extensively studied, up to 75% of adult patients with ITP may develop chronicity, which represents a significant burden on patients’ quality of life. A major risk of ITP is bleeding, but knowledge on the exact relationship between the degree of thrombocytopenia and bleeding symptoms, especially at a lower platelet count, is lacking. The actual management of ITP is based on immune suppression (corticosteroids and intravenous immunoglobulins), or the use of thrombopoietin receptor agonists (TPO-RAs), rituximab, or spleen tyrosine kinase (Syk) inhibitors. A better understanding of the underlying pathology has facilitated the development of a number of new targeted therapies (Bruton’s tyrosine kinase inhibitors, neonatal Fc receptors, strategies targeting B and plasma cells, strategies targeting T cells, complement inhibitors, and newer TPO-RAs for improving megakaryopoiesis), which seem to be highly effective and well tolerated and result in a significant improvement in patients’ quality of life. The disadvantage is that there is a lack of knowledge of the predictive factors of response to treatments, which would help in the development of an optimized treatment algorithm for selected patients.